A survey of DNA packaging in vivo and in vitro during infections caused by T4 DNA-delay and DNA-arrest amber mutants revealed a common DNA packaging-deficient phenotype. Electron microscopy revealed high proportions of proheads partially filled with DNA in vivo, indicating normal initiation but incomplete encapsidation. In contrast, exogenous mature T4 DNA was packaged in vitro by several early-gene mutant extracts. Detailed analysis of gene ts39 mutants (subunit of topoisomerase II) showed that in vivo packaging is defective, yet expression of late proteins appeared normal and the concatemeric DNA was not abnormally short or nicked. Although g39 amber mutant extracts packaged DNA in vitro, two of three ts39 mutant extracts prevented encapsidation of the exogenous DNA. The temperature-sensitive (ts) gp39 in a mutant topoisomerase II complex may have interfered with packaging in vivo and in vitro by interacting with DNA in an anomalous fashion, rendering it unfit for encapsidation. These results support the hypothesis that T4 DNA packaging is sensitive to DNA structure and discriminates against encapsidation of some types of defective DNA.
Numerous bacteriophage T4 gene products required for DNA replication, recombination, and repair interact with concatemeric DNA, yet their functions, if any, in DNA packaging are largely unknown. A few of these functions are, however, known to be required for DNA packaging by more or less well defined mechanisms. Packaging is blocked in T4 gene 49 mutants because branches formed during recombination are not removed by the mutant gp49 endonuclease (13, (21) (22) (23) . Inactivation of T4 DNA ligase (g30) following normal DNA and prohead synthesis introduces a reversible block to the completion of packaging, probably because unrepaired nicks in the DNA block encapsidation (3, 4, 9, 38) . Infections caused by T4 deoxyribonucleosidespecific 3'-phosphatase (psel) mutants in some host strains are thought to accumulate 3'-phosphoryl termini in the DNA which may block packaging (7) . Encapsidation of UVirradiated T4 DNA in vivo is slowed owing to the formation of thymine dimers in repair-deficient infections (denV-) and by the DNA structural changes incurred during repair processes in repair-competent infections (39) . DNA-delay suppressing (dar) mutations cause slow repair of uncharacterized structural abnormalities in gene 59 mutant DNA which presumably block packaging (36, 37) . Mosig et al. (25) provided genetic evidence of an interaction between the T4 helix-destablizing protein (gp32) and gpl7, a T4 packaging protein, and proposed that competitive or interactive reactions occur between DNA recombination (early-gene functions) and initiation of DNA packaging (late-gene functions; 24). These and other results suggest that many early-gene functions which primarily affect DNA replication might also influence T4 DNA packaging. However, except for the examples above and T4 DNA polymerase (gp43), which does not block packaging if inactivated following normal DNA and prohead synthesis (10, 38) , the roles of most early-gene products in DNA packaging have yet to be demonstrated.
Assessment of the effects of early-gene mutations on packaging is quite difficult, in part because early-gene functions and DNA synthesis are required for late proteins to be synthesized. Use of the cs2O mutation in conjunction with a * Corresponding author.
given early-gene temperature-sensitive (ts) mutation can in some cases overcome this problem (9) . However, the uncertain nature of the ts mutations available in many of the early genes limits the applicability of such studies. For the mutations discussed above (in genes 30 and 43), the mutant gene products have a well-defined function in DNA metabolism and are known to be inactivated upon a shift to nonpermissive temperatures. However, other early-gene functions are less well characterized biochemically, and the mutant gene products may be temperature inactivated only if synthesized at the nonpermissive temperature. Thus, in the latter case, packaging of DNA following a temperature shift does not indicate a lack of involvement in packaging. Overlapping of certain phage and host functions (e.g., ligase, topoisomerase) further complicates the interpretation of such packaging studies.
An in vitro packaging assay for T4 has been developed which measures the encapsidation of exogenous DNA into preformed proheads (2) . This assay may provide a means of assessing gene products needed for packaging and recombination. However, in vitro packaging does not display certain in vivo requirements, e.g., mature phage DNA is more efficiently packaged than concatemeric DNA in vitro (2) . Nevertheless, correlation with in vivo studies allows the verification of ts early-gene products required for DNA encapsidation and could allow the identification of mutant gene products which convert DNA from a packagingcompetent to a packaging-defective form.
Studies of packaging in vivo which do not involve temperature shift experiments are limited to mutant infections in which some concatemeric DNA and late proteins are synthesized. DNA in these cases might have structural defects which later impair packaging and result in increased amounts of empty or partially filled head structures. We considered the DNA-delay (DD) and DNA-arrest (DA) mutants as candidates for this type of packaging impairment, especially the T4 topoisomerase II mutants (DD), which may affect late DNA topology. A unique rIIB frameshift mutant (FC238) which produces a mutant toxic polypeptide proposed to insert into the cell membrane and possibly inhibit DNA packaging was also included in our study (1, 11, 17, 28 The kinetics and extent of DNA packaging in vivo were assessed by using electron microscopy to enumerate profiles of maturing head structures in thin-sectioned T4-infected cells (in all cases, more than 200 head structures were counted). The packaging transition from empty proheads to partially filled heads to full heads can be clearly monitored by this procedure. Previous studies have shown that this microscopy technique is reproducible and allows accurate assessment of the amount of DNA packaging into proheads independent of the ultimate infectivity of the virions produced. A decline in packaging is shown by the presence of elevated proportions of empty or partially filled proheads in a given infection (see Fig. 1 ). The general features of head structure enumeration and the statistical validity of the method have been previously described in detail (38, 39) .
In vitro packaging experiments. The procedures used for in vitro packaging were those described by Black (2) . To assess the effects of packaging extracts on exogenous DNA, the in vitro packaging procedure was followed except that prohead-deficient mutants (am23) were used and the exogenous phage DNA was labeled with [3H]thymidine (by the methods of Zachary and Black [38] 
RESULTS
An electron-microscopic determination of in vivo DNA packaging during infections by T4 amber DD and DA mutants revealed elevated proportions of partially filled heads under nonpermissive conditions, providing direct evidence of a common DNA packaging-deficient phenotype (Table 1) . Since the proportion of empty proheads was low in these infections, the defect was evidently in the completion rather than the initiation of encapsidation. Mufti and Bernstein (27) , on the basis of phage yields, observed the suppression by growth temperature of the amber phenotype in several DD mutants (g58-61, g52, g39). We found that temperature suppression of the packaging deficiency also occurred in these amber mutants (Table 1 ; Fig. 1D ).
In contrast to the effects in vivo, exogenously added mature T4 DNA was encapsidated by extracts from several early-gene mutant infections in vitro, producing phage yields at high and low temperature that were not significantly different from those of a cs20rIIA control extract (Table 2 ).
These results suggested that some early gene functions may not be required to package structurally normal DNA, yet deficiency early in an infection may produce packagingdefective concatemeric DNA. Initially the cs2Ots39(A41) T4 topoisomerase II extract was the only mutant early-gene extract which failed to encapsidate exogenously added DNA at either 30 or 39.5°C and reduced the extent of packaging when added to a control extract (see footnote a in Table 2 ). Subsequently, complementation testing and recombination mapping established that a previously uncharacterized H6 ts mutation, isolated by C. Hsiao, was in gene 39 at a locus different from the two other ts g39 mutations (Fig. 2) . The cs2OtsH6 extracts, like the cs2OtsA41 extracts, would not encapsidate exogenously added DNA in vitro (Table 2) . Although these two ts39 mutants blocked packaging in vitro, DNA was encapsidated by am39 or ts39(G41) extracts. These intriguing indications about the DNA packaging role of g39 led us to select gene 39 mutants for detailed study.
In vivo packaging measured by phage yields in temperature shift experiments suggested that topoisomerase II activities are not required for encapsidation of DNA (Table 3) . A ts24am39 and a ts24 mutant infection (g39+ control) were incubated at 42°C, allowing DNA synthesis (18, 26) and the formation of prohead I structures which are maturable upon a shift to 25°C in the presence of chloramphenicol. Since the phage yields after the shift to 25°C were not significantly different between the two infections and since the presence of coumermycin did not significantly affect the yields, DNA was packaged in the apparent absence of both the gene 39 topoisomerase II subunit and the DNA gyrase activity (Table 3) . Cells infected with cs20ts39 (A41 or G41) mutants at 20°C accumulated empty proheads and normal DNA. After the shift to 42°C that initiated synchronous DNA packaging, the levels of DNA encapsidation in these ts mutants were compared with those for a cs20ts2l infection. In one experiment, coumermycin was added to one of two replicate infections 5 min prior to temperature shift and chloramphenicol was added to each infected culture at the shift to prevent further synthesis of head proteins (Table 3 ). In the second experiment, inhibitors were not added, but samples for microscopy were taken early after the shift to 42°C (Table 3) . In samples from the g39 mutant infections, DNA packaging was initially slower than for the control infection, yet with time overall packaging levels and phage yields were only slightly reduced (Table 3) . Any reduction in packaging in these experiments is significant because it occurs in the presence of a large pool of packagable DNA (made at 20°C). We determined that temperature-reversible inactivation of the ts enzymes occurs because in vitro at 30°C topoisomerase II activity is detected in the ts39 extracts made at 25 and 42°C, but assay of the same extracts at 42°C shows no activity (assay conditions were those of Liu et al. [16] ; data not shown). We therefore assume that the ts39 protein in the topoisomerase II complex is also inactivated upon the shift to 42°C in vivo and in some way impairs the encapsidation of some of the DNA. The addition of coumermycin caused a similar reduction in packaging and yield in both topoisomerase-competent and -defective infections (Table 3) ; its effect is therefore likely to be on late-protein synthesis (18, 26) . These results demonstrate that neither gp39 (and presumably T4 topoisomerase II) nor DNA gyrase activity is required to encapsidate structurally normal DNA in vivo or in vitro. However, the presence of ts mutant gp39 in vivo does impair packaging, and in vitro two ts39 mutants prevented the packaging of exogenously added DNA.
Comparison of in vivo encapsidation of the ts39 mutant infections (relative to the wild type) at two late points (DNA elongation is presumably normal [18, 19] ) suggested that the lowered level of packaging was not simply due to a delay in normal phage maturation caused by delayed DNA synthesis. Packaging and phage yields were reduced at 35 min postshift, increased slightly in the subsequent 15 min, but did not approach the control levels (Table 4 ; Fig. 1A through C) . Thus, at nonpermissive temperatures we observed (presumably in the presence of compensatory gyrase activity) a continuation of reduced packaging. This provided further evidence that the diminution of packaging occurs because the ts39 mutant topoisomerse II complex is present.
In related experiments, synthesis of late proteins was inhibited late in the infection to increase the concentration of DNA relative to that of proheads. In the tsA41 and H6 mutant (and the wild-type) infections, addition of chloramphenicol decreased the yield of phage but did not change the proportion of partially filled and full heads (Table 5 ). This suggested that any partially filled heads present were not the result of too little DNA for packaging. Since some increase in the number of full heads was seen in the G41 mutant, a scarcity of DNA relative to proheads might have in part contributed to the reduction in packaging. In G41 infections, both the amount of DNA (either with continuous or pulsechase labeling) and of head structures per cell profile (a measure of late protein synthesis) synthesized were 10% that in a wild-type infection, whereas the value was 50% for the A41 and 70% for the H6 mutants ( Fig. 1 A through C; other data not shown). Therefore, despite variable diminution of DNA synthesis, the levels of DNA and late proteins seemed to be in relative balance in these infections, even in the G41 mutant.
A pulse-chase study (pulse at 15 mpi, chase from 18 to 40 mpi at 42°C) of late protein synthesis in the ts39 mutants showed that prohead maturation proteolysis of gp23 occurs later than in a wild-type infection, reflecting the delay phenotype of the ts39 mutants. However, no significant differences among the relative levels of late proteins synthesized were observed, and by 40 mpi cleavage of gp23 was complete (data not shown). Since the pattern of late gene expression appears normal in the ts39 mutants, there is no evidence the packaging defect results from aberrant late gene expression.
The sedimentation characteristics of concatemeric DNA produced in vivo during packaging-deficient (am23) ts39 mutant infections were assessed in neutral sucrose gradients. DNA from an am23 mutant infection served as a measure of the sedimentation position of normal unpackaged concatemeric DNA. No significant differences were observed in the position of concatemeric DNA available for encapsidation among the mutants and the control, so that the presence of large amounts of short DNA alone could not explain the elevated proportion of partially filled heads observed in vivo (Fig. 3) . Sedimentation under alkaline conditions revealed no significant differences between mutant and control DNA, indicating no excessive nicking of the concatemeric DNA (data not shown). After exposure to ts39am23 packaging extracts in vitro (am23 mutant extract served as a control), exogenously added mature DNA sedimented slightly faster in neutral sucrose than did untreated DNA, but there were no significant differences between the sedimentation characteristics of the mutant and control extract-treated DNAs (data not shown).
We observed no significant shortening of DNA molecules in vivo or in vitro in the ts39 mutant infections and therefore conclude that the formation of partially filled heads and the block to in vitro packaging were not due to production and encapsidation of abnormally short DNA molecules. Treatment of DNA with detergent links bound T4 topoisomerase II or DNA gyrase molecules to the DNA, trapping covalently bound gp52-DNA strand-passing intermediates and ultimately forming double-strand breaks in the DNA (8, 14, 16, 30, 34) . Thus, our failure to observe shortening of DNA molecules (treated with sodium dodecyl sulfate prior to centrifugation) provides an indication that either the ts39 mutant topoisomerase molecules may not bind to the DNA or they may bind abnormally and not form cleavable reaction intermediates.
Examination of the rIIB(FC238) mutant showed that although the level of DNA synthesis was about half that in a T4 wild-type infection, apparently normal concatemeric DNA was synthesized (Fig. 3) and late-protein patterns and processing were as in the wild type (data not shown). Since we observed large proportions of apparently full heads but few viable phage progeny, we conclude that the rIIB(FC238) mutant does not cause a morphologically detectable defect in DNA packaging (Table 1) .
DISCUSSION
The mutations we examined are in early T4 genes whose products are, by generally ill-defined mechanisms, involved in DNA processing (replication, repair, and recombination). These mutations affect the formation and structure of concatemeric DNA, yet under nonpermissive conditions some DNA, late proteins, and viable phage progeny are produced. Some of these mutants had previously been supposed from biochemical studies (e.g., DNA sedimentation) to be defective in DNA packaging. We have demonstrated by direct in vivo electron-microscopic observation that all of these DD and DA mutants do in fact accumulate abnormally high proportions of proheads partially filled with DNA. This indicates a morphologically similar DNApackaging defect; impaired completion of DNA encapsidation into proheads in which packaging has been initiated. At the same time, we did not observe such an encapsidation defect in the rIIB(FC238) mutant in which defective DNA packaging had been suspected (28) . Failure to complete encapsidation in the DD and DA mutants indicated that the packaging proteins and proheads were competent to initiate and translocate DNA into proheads. In vitro, all of the mutants tested (with the exception of two ts g39 mutants discussed below) were able to package exogenously added DNA. This indicated that the packaging machinery is functional and that the early-gene products tested are not required to encapsidate structurally normal DNA. Thus, the data suggested that defective early gene products may impair packaging by affecting the substrate for encapsidation, concatemeric DNA.
Mutants of gene 39 were chosen for further study as the most interesting of this group of packaging-deficient earlygene mutants. The product of gene 39 has DNA-independent ATPase activity, binds DNA, and interacts with gp52 and gp6O to form the T4 topoisomerase 11 (12, 16, (18, 19, 26) . A host factor, presumably DNA gyrase, compensates for the am39 defect at high temperatures (18, 26 Infections by the ts39(G41) mutant showed significantly lower in vivo levels of DNA synthesis, late protein synthesis, and DNA packaging than did the other ts39 infections. Like the am39 mutation, the G41 mutation did not block packaging in vitro. These results, although in accord with other studies of this mutation, were surprising (35) . The recent finding that the G41 phage contained a second ts mutation in the gene (nrdB) for the beta subunit of the T4 ribonucleoside diphosphate reductase provides an explanation for the reduced level of DNA and late protein synthesis observed (6) . It was only in the tsG41 nrdB and not other ts39 mutant infections that in vitro packaging was observed. The G41 mutant topoisomerase may differ from the other ts39 mutant enzymes; however, it is also possible that the levels of G41 mutant topoisomerase or packaging-defective endogenous DNA may have been too low to interfere with packaging of exogenously added DNA.
Overall, our data support a hypothesis that the ts39(A41) and ts39(H6) [and possibly ts39(G41)] mutant gene products, as part of a mutant topoisomerase II complex, may bind aberrantly to and perhaps structurally alter DNA in vivo and in vitro, thereby preventing packaging. Sedimentation analysis of ts39 DNA from in vivo and in vitro experiments revealed no significant DNA structural anomalies and no strand breakage indicative of gp52 binding and strandpassing activity. Temperature shift and in vitro packaging experiments with the am39 mutant indicated that packaging of normal DNA occurs in the absence of topoisomerase II function, yet in vivo and in vitro the presence of the ts mutant gp39 diminished the level of packaging. The finding that topoisomerase activity is associated with the gp52 subunit and that a tight DNA binding is associated with the amino-terminal portion of the gp39 subunit of T4 topoisomerase II are also in accord with our DNA binding hypothesis (11, 30; Huang et al., Abstr. Fifth Intl. T4 Evergreen Meeting 1985).
We have shown that although defective early gene products can reduce DNA packaging (presumably by effects on the concatemeric DNA), some of these gene functions are not absolutely required for encapsidation of normal DNA. The ts mutations of gene 39 may be an instance of a defective early-gene product which can interact with DNA late in infection and impair the completion of encapsidation. These results are consistent with the hypothesis that DNA packaging has evolved to be sensitive to DNA structure and acts to halt encapsidation of some DNA which can be considered packaging defective.
